Sanofi pays $80M to add Roche-rivaling Fulcrum drug to phase 3 rare disease pipeline

[cafead]

via Sanofi is betting $80 million upfront on a GSK castoff ahead of a phase 3 readout. Fulcrum Therapeutics took the other side of the deal, handing Sanofi ex-U.S. rights to a rare disease candidate that is leading Roche in a race to market.

article source